著者

松原 肇 矢後 和夫

出版者

日本静脈経腸栄養学会

雑誌

静脈経腸栄養 (ISSN:13444980)

巻号頁・発行日

vol.24, no.6, pp.1169-1174, 2009 (Released:2009-12-21)

参考文献数

10

被引用文献数

1

---

TPN施行時の輸液フィルター使用は, 感染防止, 塞栓防止の観点から有用である. しかし, 薬剤によっては, 輸液フィルターに吸着され, 場合によっては, 治療に影響を及ぼす場合がある. 本稿では, 輸液フィルターへの薬剤吸着の機序, 考え方などについて述べる.

著者

熊谷 雄治 藤田 朋恵 横田 愼一 澤田 実花 井澤 志名野 鈴木 勇一 立岡 和弘 庄田 隆 矢後 和夫

出版者

The Japanese Society of Clinical Pharmacology and Therapeutics

雑誌

臨床薬理 (ISSN:03881601)

巻号頁・発行日

vol.33, no.5, pp.205-213, 2002-09-30 (Released:2010-06-28)

参考文献数

8

---

Objectives: Tibolone (KB-889) is a novel compound that possesses tissue-specific hormonal effects. We investigated the pharmacokinetics of tibolone in postmenopausal women in four pharmacokinetic studies, namely a dose linearity study, a multiple dose study, a study in fasted condition, and a study in elderly. In this report, the results obtained from the above four studies are summarized.Methods: In the dose linearity study, a single dose of 0.5 mg, 1 mg and 2 mg of tibolone was administered to 6 postmenopausal women using a 3-period crossover method with at least a 7-day wash-out period between treatments. In the multiple dose study, 2 mg of tibolone was administered once daily for 4 days to 6 postmenopausal women. In the study in fasted condition, a single dose of 2 mg of tibolone was administered to 6 postmenopausal women after overnight fasts. In the study in elderly, a single dose of 2 mg of tibolone was administered to 6 elderly women aged 65 or older. Plasma and urine concentrations of tibolone and its metabolites were measured.Results and Conclusion: Plasma concentrations of the 3α-OH and 3β-OH metabolites of tibolone were measured, since the levels of tibolone and its Δ4-isomer were under or near the detection limits. After single dose administration of 0.5, 1 and 2 mg of tibolone, the means of Cmax and AUC0-12h of plasma 3α-OH metabolite were 2.3, 3.5 and 6.5 ng/mL and 10.2, 18.5 and 36.7 ng·Eh/mL, respectively, and those of 3β-OH metabolites were 0.9, 1.7 and 3.1 ng/mL and 4.6, 8.8 and 17.7 ng·Eh/mL, respectively. The means of Tmax and T1/2 (6-12h) of plasma 3α-OH and 3β-OH metabolites were between 3.7 and 5.7 h, and between 3.2 and 4.4 h, respectively. The pharmacokinetic properties of tibolone were considered to be linear within the dose range of 0.5 mg to 2 mg. In the multiple dose study, no accumulation was found. When comparing the pharmacokinetic parameters obtained from the study in fasted condition with those of day 1 of the multiple dose study, the absorption of tibolone was rapid under fasted condition, but AUC was not influenced by food intake. [The means of Tmax of 3α-OH and 3β-OH metabolites were 1.17 and 1.33 h in fasted condition, and 3.83 and 4.00 h on day 1 of multiple dose.] Finally no difference in pharmacokinetics was found between postmenopausal women and elderly women in the comparison of the pharmacokinetic parameters obtained from the study in the elderly and those of day 1 of the multiple dose study.

著者

黒山 政一 尾鳥 勝也 矢後 和夫

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.29, no.3, pp.287-293, 2003-06-10 (Released:2011-03-04)

参考文献数

7

---

Over 100 pharmaceutical products are withdrawn from the market in Japan each year. Nonetheless, there has so far been no report consisting of a specific survey of the volume of work borne by the medical organizations related to such with drawals. As are sult, a survey of the response of medical organizations and the volume of work have been made regarding the withdrawal of Maalox ®in August 2000.Our findings revealed that a considerable amount of time, namely 4, 502 minutes was expended regarding the withdrawal of this product at Kitasato University East Hospital. A total of 2, 770 minutes, or 62% of the total time was spent within 24 hours after receiving the announcement of the drug's removal from the market. When the total time was broken down by job type, 3, 188 minutes, or 71% of the total, were spent by pharmacists A further, 2, 315 minutes, or 52% of the total, were used to determine how to best respond to the matter.In order to efficiently recall pharmaceutical products, an operation was established which was thereafter distributed to all concemed staff members.The total time spent on the withdrawal of Maalox ® was estimated to have utilized approximately ¥285, 000of labor cost, based on the average wages of the employees. As a result, hospitals are forced to bear a significant economic burden whenever such products are withdrawn.Finally, pharmaceutical manufacturers should be equipped with the systems for manufacture and supply as much as possible to minimize such recall incidents. When drug are unavoidably withdrawn, however, the manufacturers should nevertheless provide all appropriate information as quickly as possible to the related medical organizations while carefully taking the economic burden that such organizations must bear into consideration.

著者

尾鳥 勝也 田口 祐子 矢後 和夫

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.31, no.9, pp.761-767, 2005-09-10 (Released:2011-03-04)

参考文献数

7

被引用文献数

5 6

---

We studied the quality and stability of generic sodium ozagrel solution products for injection. Through the use of inspection apparatus, we noted exfoliation of the surface layer of glass ampoules filled with sodium ozagrel solution drug products for injection. Also, foreign insoluble matter, such as oil droplets, which was assumed to be silicone that had been applied to the internal surface of syringe barrels, was observed in pre-filled syringe products. In a stability study performed under accelerated conditions (40°C/75% RH) the generic sodium ozagrel solutions yielded a degradation product that was not detected in the lyophilized original product. The degradation product content of some of the generic products was over 16 mg/mL of sodium ozagrel, exceeding the specification for the original lyophilized product. These results indicate that some of the generic products are inferior in quality and stability to the original lyophilized drug.

著者

木村 公美 三橋 真由美 奈良輪 知也 尾鳥 勝也 矢後 和夫 伊藤 智夫

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.38, no.12, pp.751-756, 2012-12-10 (Released:2013-12-10)

参考文献数

11

被引用文献数

2 3

---

The simple suspension method has been developed for performing tubal administration by placing tablets or capsules in hot water (55 °C) and serially decaying/suspending them without crushing/opening them. However, the stability of a cardinal drug against the pH of the suspension and heat remains unclear. In this study, we examined the stability of an oral anti-tumor preparation, capecitabine tablets, against the pH of the suspension and heat. Initially, we assessed the stability of capecitabine tablets suspended in phosphate-buffered saline at various pHs. Subsequently, we investigated the stability of capecitabine tablets suspended in phosphate-buffered saline heated at 25 or 55 °C. In addition, we evaluated the stability of this preparation heated at 55 or 80 °C for 30 minutes after being suspended in phosphate-buffered saline heated at 25 °C. When capecitabine suspension was heated at 80 °C for 30 minutes under acidic conditions, the residual capecitabine rate was approximately 50%. Then, a tube passage test of capecitabine was conducted. Passage was favorable. There was no decrease in the content after passage in comparison with the pre-passage value. Based on these results, the tubal administration of capecitabine should be performed considering both the drug suspension pH and temperature.

著者

国分 秀也 とおし 幸市朗 的場 元弘 磯野 雅子 外 須美夫 矢後 和夫

出版者

日本緩和医療学会

雑誌

Palliative Care Research (ISSN:18805302)

巻号頁・発行日

vol.1, no.1, pp.311-316, 2006 (Released:2006-09-08)

参考文献数

12

被引用文献数

1 2

---

アセトアミノフェン(APAP)坐薬の成分含量は1個200mgが最大で, がん性疼痛患者に用いる場合, 海外における用量(4000mg/日上限)を目安に投与するケースがあるため, 一回に3~4個挿入しなければならない. そこで, 今回, 1個600~800mgの坐薬を調製し, その有用性について検討した. 方法は, APAP経口投与患者と直腸内投与患者の血中トラフ濃度を測定し, 副作用についても比較検討した. その結果, APAP経口投与群と直腸内投与群の血中濃度は, ほぼ同等な値を示した. また, APAP使用1週間後のAST, ALTおよび総ビリルビン値に異常値は認められなかった. さらに, APAPを経口投与から直腸内投与に切り替えた症例で, 切り替え前後でNRSに変化がなく, 血中濃度もほぼ同等な値を示していた. 以上のことから, 今回, 調製した高用量APAP坐薬はがん性疼痛患者において血中濃度と安全性に問題なく使用可能であると考えられた.

著者

国分 秀也 的場 元弘 山田 安彦 矢後 和夫

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.131, no.1, pp.113-127, 2011-01-01 (Released:2011-01-01)

参考文献数

89

被引用文献数

1 1

---

The pain experienced by cancer patients can be managed in 70-90% of cases by the World Health Organisation protocol for cancer pain. However, cancer pain treatment in Japan is not sufficiently effective. To use medicine safely and effectively, various problems must be solved. Therefore, in this study, appropriate usage of cancer pain treatment was examined. We were able to use acetaminophen suppositories (800 mg each) in cancer pain patients. It was suggested that high serum concentrations of oxycodone and hydrocotarnine might be observed in geriatric patients or in the state of decreased hepatic blood flow, making dose adjustment is necessary for such patients. We also clarified that the conversion ratio from oral oxycodone to intravenous ocycodone/hydrocotarnine was 0.71±0.12. In addition, we clarified the pharmacokinetics of controlled-release oxycodone in patients with cancer pain. Moreover, the findings of our study indicate that in the steady state, the serum concentrations of fentanyl are not maintained at a constant level for 3 days following the use of transdermal fentanyl. We established a method of appropriately passing a nasal duct for sustained release of fine granules of morphine sulfate. Resolution of the clinical problems associated with cancer pain treatments is anticipated to allow the proper use of cancer pain treatments in Japan.

著者

野中 美和 桜井 幸子 今井 伸恵 青砥 広幸 竹内 尚子 矢後 和夫

出版者

日本医療薬学会

雑誌

日本病院薬学会年会講演要旨集

巻号頁・発行日

vol.6, pp.168-169, 1996-08-21

著者

櫻井 幸子 椎 崇 尾鳥 勝也 黒山 政一 矢後 和夫

出版者

日本医療薬学会

雑誌

日本病院薬学会年会講演要旨集

巻号頁・発行日

vol.7, 1997-08-15

著者

吉山 友二 尾鳥 勝也 厚田 幸一郎 矢後 和夫 藤金 治雄 緒方 憲太郎 二神 幸次郎

出版者

日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.33, no.4, pp.365-369, 2007-04-10

被引用文献数

2

---

Elcatonin injection is used for the treatment of osteoporosis in Japan. In order to compare the original product with generic versions, we measured the elcatonin content and amounts of impurities in both using high performance liquid chromatography, and observed changes in content with time under the conditions of light exposure and shaking. We found that elcatonin content and amounts of impurities varied among the generics and that changes in content with time under the above conditions for some generics were greater than the changes for the original product. These results suggest that some generic products should not be considered to be equivalent to the original product.

著者

木村 利美 矢後 和夫

出版者

じほう

雑誌

月刊薬事 (ISSN:00165980)

巻号頁・発行日

vol.47, no.11, pp.1831-1837, 2005-10